Pharmacological Approach to Alzheimer’s disease
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Rheem, Gayoung | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Szentmiklósi, József András | |
| dc.contributor.opponentdept | Kenézy Kórház, Központi Aneszteziológiai és Intezív Terápiás Osztály | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2022-08-29T08:51:55Z | |
| dc.date.available | 2022-08-29T08:51:55Z | |
| dc.date.created | 2022-02-17 | |
| dc.description.abstract | Four dominant types of treatments were listed: cholinesterase inhibitors, NMDA antagonists, amyloid-based therapies and Vitamin E. As for cholinesterase inhibitors, it is analysed that the pharmacological and clinical action of tacrine, donepezil, galantamin and rivastigmine, whereas among the NMDA antagonists memantine is emphasized. Amyloid-based therapies include reduction of amyloid beta-production, prevention of amyloid beta accumulation and promotion of clearance. There are some words about the role of Vitamin E in treatment of this neurodegenerative disease. | hu_HU |
| dc.description.corrector | hbk | |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 37 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/336846 | |
| dc.language.iso | en | hu_HU |
| dc.subject | Alzheimer | hu_HU |
| dc.subject | Dementia | hu_HU |
| dc.subject.dspace | DEENK Témalista::Orvostudomány::Farmakológia | hu_HU |
| dc.title | Pharmacological Approach to Alzheimer’s disease | hu_HU |